Catalent Executive and Leadership Team

Christopher Hajjar, the Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer at Catalent, directs the financial architecture for the biologics division. This executive manages complex capital allocation strategies to support multi-modality manufacturing expansion across North American and European markets. By overseeing rigorous financial planning and analysis, Hajjar ensures the alignment of resource distribution with the broader corporate growth objectives. The Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer maintains constant communication with the executive leadership team to evaluate the fiscal health of ongoing drug development projects. Through precise forecasting and risk assessment, Christopher Hajjar stabilizes the financial foundation required for high-stakes pharmaceutical innovation. This leadership role demands constant vigilance over operational costs and investment returns, ultimately securing the long-term viability of the biologics segment within the global CDMO landscape.

Matti Masanovich, the Senior Vice President & Chief Financial Officer at Catalent, oversees the entire fiscal strategy and capital structure of the organization. Directing global financial reporting, the Chief Financial Officer ensures transparency and compliance while managing the balance sheet to support large-scale investments in manufacturing infrastructure. Masanovich evaluates the financial feasibility of mergers, acquisitions, and internal R&D projects to maintain a competitive edge in the pharmaceutical services market. By optimizing cash flow and managing investor relations, Matti Masanovich provides the necessary financial stability for the company to pursue long-term growth in personalized medicine. The Senior Vice President & Chief Financial Officer collaborates with other C-suite leaders to allocate resources efficiently across diverse geographic regions. Through disciplined financial oversight and strategic planning, Masanovich ensures that the company remains well-positioned to meet the evolving needs of global health partners and stakeholders.

Aris Gennadios, the Group President, Pharma & Consumer Health at Catalent, directs the operational execution of drug development and manufacturing services. Overseeing the Pharma & Consumer Health division, the Group President manages the end-to-end life-cycle supply for a diverse portfolio of products. Gennadios ensures that manufacturing facilities adhere to the highest quality standards while scaling production to meet the needs of global pharmaceutical and consumer health partners. By integrating advanced delivery technologies into the production process, Aris Gennadios enhances the efficacy and marketability of client products. The Group President, Pharma & Consumer Health coordinates with technical teams to streamline development timelines, ensuring that new therapies reach patients with maximum efficiency. Through the management of complex supply chains and manufacturing operations, Gennadios drives the operational success of the company, solidifying its reputation as a leader in the global CDMO sector.

Kassandra Walsh, the Senior Account Director & Chief Revenue Officer at Catalent, drives the commercial strategy for pharmaceutical and biotech partnerships. Overseeing global revenue streams, the Chief Revenue Officer identifies emerging market opportunities for personalized medicine and consumer health brand extensions. Walsh manages high-level client relationships, ensuring that the service offerings align with the specific development and manufacturing needs of global partners. By optimizing the sales funnel and refining contract structures, Kassandra Walsh accelerates the adoption of proprietary delivery technologies. The Senior Account Director & Chief Revenue Officer collaborates with the operations team to ensure that revenue targets reflect the actual capacity for product launches and life-cycle supply management. Through strategic market positioning and aggressive business development, Walsh secures the company's status as a preferred partner for blockbuster drug manufacturing, directly impacting the overall financial trajectory of the organization.

Lisa Evoli, the Senior Vice President and Chief Human Resources Officer at Catalent, architects the global talent strategy to support complex pharmaceutical manufacturing operations. Overseeing organizational development, the Chief Human Resources Officer implements initiatives that foster technical expertise in development sciences and delivery technologies. Evoli manages the recruitment and retention of specialized personnel across international sites, ensuring that the workforce remains capable of meeting the rigorous demands of the CDMO industry. By aligning human capital with corporate mission, Lisa Evoli drives cultural integration and performance management across all business units. The Senior Vice President and Chief Human Resources Officer works closely with the executive board to design compensation structures that incentivize innovation and operational excellence. Through the cultivation of a high-performance environment, Evoli ensures that the company maintains the necessary human infrastructure to deliver life-saving medicines to patients worldwide.